Additional file 1: of Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study
journal contributionposted on 10.04.2019, 05:00 authored by Jan Menne, Yahsou Delmas, Fadi Fakhouri, Christoph Licht, Åsa Lommelé, Enrico Minetti, François Provôt, Eric Rondeau, Neil Sheerin, Jimmy Wang, Laurent Weekers, Larry Greenbaum
Table S1. Follow-up by treatment status. Table S2. Serious targeted TEAEs during current study. Figure S1A and B. Effects on renal function based on eGFR.